Irradiation of blood products is the process of exposing cellular blood components — red blood cells, platelets, and granulocytes — to gamma or X-ray radiation before transfusion, in order to inactivate the donor’s residual T-lymphocytes. It is not a sterilization step and it does not treat bacterial or viral contamination. Its single purpose is to prevent transfusion-associated graft-versus-host disease (TA-GVHD), a rare but almost universally fatal complication in which viable donor T-cells engraft in a susceptible recipient and mount an immune attack against the recipient’s own tissue.
This is a routine, well-defined step in transfusion service operations, not an experimental or rarely-used technique. Blood banks and hospital transfusion services irradiate components on a defined schedule, driven by whether a specific patient falls into a recognized high-risk category, and the process is subject to accreditation and regulatory oversight in the same way as other critical blood-banking procedures.
What “irradiation of blood” actually means
When people search “what is irradiation of blood,” they are usually asking about this exact process: a blood bank exposes a unit of packed red blood cells, a platelet product, or a granulocyte product to a defined, measured dose of ionizing radiation from a dedicated blood irradiator (historically a cesium-137 or cobalt-60 gamma source; increasingly a self-shielded X-ray irradiator, as gamma sources are phased out in many jurisdictions for radiological-security reasons) or, less commonly, at an external radiation oncology facility using a linear accelerator.
The radiation damages the DNA of any lymphocytes present in the unit, preventing them from proliferating after transfusion, while leaving the therapeutic function of red cells and platelets essentially intact. It is distinct from irradiating food or medical devices for sterilization purposes — blood irradiation targets a specific cell population’s ability to divide, not microbial contamination.
Why blood products are irradiated: preventing TA-GVHD
Transfusion-associated graft-versus-host disease occurs when a transfused unit contains enough viable, immunologically competent donor T-lymphocytes to engraft in the recipient and recognize the recipient’s tissues as foreign. In an immunocompetent recipient, the recipient’s own immune system normally destroys these donor cells before they can cause harm. TA-GVHD arises when the recipient cannot mount that rejection response — either because of underlying immunodeficiency, immunosuppressive treatment, or a close HLA match between donor and recipient that lets the donor lymphocytes go unrecognized as foreign.
Once established, TA-GVHD typically presents one to six weeks after transfusion with fever, an erythematous or maculopapular rash, liver dysfunction, profuse diarrhea, and pancytopenia from bone-marrow aplasia caused by the donor T-cells attacking the recipient’s marrow. Unlike graft-versus-host disease after a stem-cell or bone-marrow transplant, TA-GVHD has essentially no established treatment once symptomatic, and case-fatality rates are consistently reported above 90%. Because there is no reliable treatment, prevention through irradiation of the blood product before it reaches an at-risk patient is the entire clinical strategy.
How gamma and X-ray irradiation actually work
A blood irradiator delivers a validated, dosimetry-confirmed radiation dose across the entire unit. Because dose intensity naturally varies with distance from the source and with the unit’s position in the canister, blood-bank irradiators are validated to guarantee a defined minimum dose at every point in the unit, not just at its center. Under the widely followed standard used in AABB-accredited transfusion services in the United States, this means a minimum of 25 Gy delivered to the mid-plane of the container, with no point in the unit receiving less than 15 Gy. Irradiators are periodically re-validated with dosimetry film or ion-chamber measurements to confirm they still meet this specification as the radioactive source decays (for gamma sources) or as the unit ages.
At these doses, lymphocyte DNA is damaged badly enough to prevent the cells from proliferating in response to the recipient’s tissue antigens, which is what actually prevents TA-GVHD — irradiation does not remove or lyse the lymphocytes, and a irradiated unit will still test positive for intact white cells on a differential count. Red cells and platelets, which do not need to divide to perform their function, tolerate these doses with clinically acceptable, well-characterized effects (see the shelf-life section below).
Which blood components are irradiated
Irradiation applies only to components that contain viable nucleated cells capable of engraftment:
- Red blood cell (RBC) units — the most commonly irradiated component.
- Platelet products (both whole-blood-derived and apheresis platelets).
- Granulocyte concentrates — irradiated routinely, given their very high residual lymphocyte content.
Fresh frozen plasma, cryoprecipitate, and other plasma-derived or acellular products are not irradiated, because freezing and the absence of intact nucleated cells already eliminate any risk of donor-lymphocyte engraftment. This distinction is a common source of confusion for staff new to transfusion services: an order for “irradiated FFP” reflects a misunderstanding of what irradiation is protecting against, not a real clinical requirement.
Indications for irradiation of blood products
Transfusion services maintain standing protocols identifying which patients require irradiated cellular components. Recognized high-risk indications include:
- Intrauterine transfusions and exchange transfusions in neonates, and transfusions to premature or low-birthweight infants, whose immune systems have not fully matured.
- Congenital cellular immunodeficiency syndromes (e.g., severe combined immunodeficiency), where the recipient cannot reject donor lymphocytes at all.
- Hematopoietic stem cell transplant (HSCT) recipients, both before and after transplant, and related allogeneic or autologous marrow/stem-cell donors during the peri-transplant period.
- Patients being treated with purine analog chemotherapy (e.g., fludarabine, cladribine, clofarabine) and certain other T-cell-depleting or immunosuppressive regimens, because these agents profoundly suppress the recipient’s own T-cell function.
- Hodgkin lymphoma patients, who have a recognized, disease-specific defect in cellular immunity independent of treatment.
- Recipients of HLA-matched or HLA-selected platelets, and directed donations from blood relatives, because a close genetic match between donor and recipient makes it more likely the recipient’s immune system will fail to recognize donor lymphocytes as foreign.
- Recipients of granulocyte transfusions, essentially universally, given the cell content of that product.
Institutional policies vary in exactly how they scope some of these categories (for example, how long post-HSCT irradiation is continued, or whether all solid-organ transplant recipients are included), so transfusion medicine physicians and blood bank medical directors set the specific institutional criteria rather than relying on a single universal list. Ordering clinicians who are uncertain whether a patient qualifies should default to consulting the transfusion service rather than guessing, given the near-certain fatality of a missed case.
Irradiation’s effect on blood product shelf life
Irradiation damages the red cell membrane enough to accelerate potassium leakage from the cell into the surrounding storage medium and to shorten the cell’s usable storage life. For this reason, irradiated red blood cell units are commonly restricted to a maximum post-irradiation storage period well short of the standard 42-day shelf life for non-irradiated RBCs — a limit widely implemented as 28 days from the date of irradiation, or the unit’s original expiration date, whichever comes first. This shortened window, combined with the elevated extracellular potassium in an irradiated unit, is part of why intrauterine and large-volume neonatal exchange transfusions specifically require freshly irradiated (and often washed) red cells rather than an older irradiated unit pulled from routine stock.
Platelet products are not subject to the same post-irradiation shelf-life reduction, since platelets do not carry the same potassium-leak risk; irradiated platelets are generally usable for their normal shelf life.
Irradiation vs. leukoreduction: not the same process
Irradiation and leukoreduction are frequently confused because both processes involve white blood cells in a transfused unit, but they solve different problems and neither substitutes for the other:
- Leukoreduction physically filters most leukocytes out of the unit, primarily to reduce febrile non-hemolytic transfusion reactions, cytomegalovirus (CMV) transmission risk, and HLA alloimmunization.
- Irradiation leaves the leukocytes physically present but disables their ability to proliferate, specifically to prevent TA-GVHD.
Leukoreduction alone does not remove enough lymphocytes to reliably prevent TA-GVHD in a patient who needs irradiation, and irradiation alone does not address the other reasons a unit might be leukoreduced. Many units are both leukoreduced and irradiated when a patient’s clinical situation calls for both, and transfusion services typically order them as separate, independently documented specifications on a blood product request rather than assuming one implies the other.
Regulatory and accreditation context
In the United States, irradiation practice sits inside the broader framework transfusion services already operate under for cellular blood component modification: AABB Standards for Blood Banks and Transfusion Services, FDA regulation of blood establishments, and CAP (College of American Pathologists) laboratory accreditation checklists all address irradiation dosimetry validation, irradiator quality control, labeling of irradiated units, and record-keeping tying a specific irradiation event to a specific unit and a specific irradiator’s calibration status. A transfusion service’s irradiation program is inspected as part of these accreditation cycles alongside its broader GxP-style quality-system requirements and, where the laboratory itself is CLIA-regulated, alongside its CLIA certification status. Institutions should verify current dosimetry and labeling requirements against their accrediting body’s live standards rather than relying solely on a secondary summary, since irradiator validation intervals and specific dose language are the kind of operational detail that gets revised between standard editions.
Frequently asked questions
What is irradiation of blood?
Irradiation of blood is the process of exposing a unit of red blood cells, platelets, or granulocytes to a validated dose of gamma or X-ray radiation before transfusion, to inactivate donor T-lymphocytes and prevent transfusion-associated graft-versus-host disease in susceptible recipients. It does not sterilize the unit or address infectious contamination.
What is the difference between irradiation and a standard blood transfusion process?
Irradiation is an additional processing step applied to a unit before it is issued for transfusion — it is not part of every transfusion. Only units going to patients with a recognized indication (see above) are irradiated; most transfusions use non-irradiated cellular components.
What are the indications for irradiation of blood products?
The core recognized indications are intrauterine and neonatal exchange transfusions, congenital cellular immunodeficiency, hematopoietic stem cell transplant recipients, purine-analog chemotherapy recipients, Hodgkin lymphoma, HLA-matched or directed-donor components, and granulocyte transfusions. See the indications section above for detail; institutional policy sets the exact scope.
Does irradiation make blood safer from infection?
No. Irradiation targets the proliferative capacity of donor lymphocytes to prevent TA-GVHD; it plays no role in inactivating bacteria, viruses, or other infectious agents, which are addressed through donor screening, infectious-disease testing, and (for some products) separate pathogen-reduction technologies.
Related CASRAI resources: GxP Compliance: What GLP, GCP, GMP, and GDP Actually Require, CLIA Certification: Certificate Types, Complexity Categories, and Whether Your Lab Needs One, Bloodborne Pathogens Training for Research Personnel: OSHA Requirements, and Good Clinical Laboratory Practice (GCLP).
